Natixis Advisors LLC Purchases 1,337 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Natixis Advisors LLC increased its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 3.0% in the 4th quarter, HoldingsChannel reports. The firm owned 45,683 shares of the company’s stock after acquiring an additional 1,337 shares during the quarter. Natixis Advisors LLC’s holdings in Crinetics Pharmaceuticals were worth $2,336,000 at the end […]
More Stories
Formula One Group (NASDAQ:FWONK) Raised to Sell at StockNews.com
StockNews.com upgraded shares of Formula One Group (NASDAQ:FWONK – Free Report) to a sell rating in a research note published...
Cabot (NYSE:CBT) Upgraded to Buy at StockNews.com
StockNews.com upgraded shares of Cabot (NYSE:CBT – Free Report) from a hold rating to a buy rating in a research...
StockNews.com Upgrades Diversified Healthcare Trust (NASDAQ:DHC) to Hold
StockNews.com upgraded shares of Diversified Healthcare Trust (NASDAQ:DHC – Free Report) from a sell rating to a hold rating in...
Altria Group (NYSE:MO) Downgraded to “Hold” Rating by Deutsche Bank Aktiengesellschaft
Deutsche Bank Aktiengesellschaft downgraded shares of Altria Group (NYSE:MO – Free Report) from a buy rating to a hold rating...
United Parcel Service (NYSE:UPS) Price Target Cut to $90.00 by Analysts at Barclays
United Parcel Service (NYSE:UPS – Get Free Report) had its price objective dropped by equities researchers at Barclays from $100.00...
Zepp Health (NYSE:ZEPP) PT Set at $13.87 by Fundamental Research
Fundamental Research set a $13.87 target price on Zepp Health (NYSE:ZEPP – Free Report) in a report released on Tuesday,BayStreet.CA...